cGMPs and Compliance Resource Center
Design and implementation of a compliance process with global governance: a case study
Ending the up-hill battle of Paper-based validation document control
FDA final guidance detailing the types of actions, inaction, and circumstances that the FDA considers to constitute delaying, denying, or limiting inspection, or refusing to permit entry or inspection.
White Papers: In Depth Research
Solutions Update: Quality, Compliance, Regulatory and Risk Management Solutions for the Increasingly Complex Pharmaceutical Industry
Posted: Sep 02, 2014
While market globalization has opened opportunities for pharmaceutical manufacturers, it has also intensified competition and the pressure to produce faster and at a lower cost.
Posted: Jul 30, 2014
Posted: Jul 29, 2014
Posted: Jul 14, 2014